RT Journal Article
T1 Proactive Immunotherapeutic Approaches against Inflammatory Breast Cancer May Improve Patient Outcomes
A1 Alonso Miguel, Daniel
A1 Fiering, Steven
A1 Arias Pulido, Hugo
AB Inflammatory breast cancer (IBC) is highly metastatic at the onset of the disease with no IBC-specific treatments, resulting in dismal patient survival. IBC treatment is a clear unmet clinical need. This commentary highlights findings from a recent seminal approach in which pembrolizumab, a checkpoint inhibitor against programmed cell death protein 1 (PD-1), was provided to a triple-negative IBC patient as a neoadjuvant immune therapy combined with anthracycline-taxane-based chemotherapy. We highlight the findings of the case report and offer a perspective on taking a proactive approach to deploy approved immune checkpoint inhibitors. On the basis of our recently published research study, we propose in situ vaccination with direct injection of immunostimulatory agents into the tumor as an option to improve outcomes safely, effectively, and economically for IBC patients.
PB MDPI
YR 2022
FD 2022-09-13
LK https://hdl.handle.net/20.500.14352/108213
UL https://hdl.handle.net/20.500.14352/108213
LA eng
NO Alonso-Miguel, D., Fiering, S., & Arias-Pulido, H. (2022). Proactive Immunotherapeutic Approaches against Inflammatory Breast Cancer May Improve Patient Outcomes. Cells, 11(18), 2850. https://doi.org/10.3390/cells11182850
NO Contrato de Ayudante 2110/AYU/011 de Daniel Alonso Miguel
NO National Cancer Institute (NCI)
NO Universidad Complutense de Madrid
DS Docta Complutense
RD 28 abr 2025